Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study.

Immunogenicity after vaccination of COVID-19 vaccines in patients with cancer: a prospective, single center, observational study.

Publication date: Feb 21, 2024

Patients with cancer, particularly those undergoing chemotherapy, are at risk from the low immunogenicity of Coronavirus Disease 19 (COVID-19) vaccines. This prospective study assessed the seroconversion rate of COVID-19 vaccines among patients with cancer and hospital staff. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein-specific IgG (S-IgG) concentrations were evaluated before the first vaccination, and 1-3 and 4-6 months after the second vaccination. The primary endpoint was the seroconversion rate measured 1-3 months after the second vaccine. In total, 590 patients and 183 healthy hospital staff were analyzed. At 1-3 months after the second vaccination, the S-IgG antibody concentration exceeded the cut-off value (20 BAU/mL) in 96. 1% (567/590) of the patients with cancer and 100% (183/183) of the healthy controls (p = 0. 0024). At 4-6 months after the second vaccination, the S-IgG antibody concentration exceeded the cut-off value (20 BAU/ml for S-IgG) in 93. 1% (461/495) of the patients with cancer and 100% (170/170) of the healthy controls (p 

Open Access PDF

Concepts Keywords
6months Cancer patients
Cancer Cancer treatments
Coronavirus COVID-19 vaccine
Severe Immunogenicity
Vaccination SARS-CoV-2

Semantics

Type Source Name
disease VO vaccination
disease MESH COVID-19
disease MESH cancer
disease MESH seroconversion
drug DRUGBANK Etoperidone
disease VO Severe acute respiratory syndrome coronavirus 2
disease VO vaccine
disease IDO history
drug DRUGBANK Human Serum Albumin
drug DRUGBANK Platinum
drug DRUGBANK Lauric Acid
drug DRUGBANK Coenzyme M
drug DRUGBANK Trestolone
disease MESH morbidity
drug DRUGBANK Stavudine
disease MESH death
disease IDO blood
disease MESH complications
disease MESH hypertension
disease MESH autoimmune diseases
disease VO protocol
disease VO dose
disease MESH subclinical infection
disease MESH infection
disease VO time
disease VO vaccinated
disease VO dead
disease VO antibody titer
disease MESH carcinoma
disease MESH Melanoma
pathway KEGG Melanoma
disease MESH Thymic carcinoma
disease IDO immune response
disease MESH Gastrointestinal Stromal Tumor
disease MESH adenoid cystic carcinoma
disease MESH duodenal cancer
disease MESH carcinoid
disease MESH angiosarcoma
disease MESH leiomyosarcoma
disease MESH liposarcoma
disease MESH esophageal cancer
disease MESH malignant pleural mesothelioma
disease MESH appendix cancer
disease MESH thyroid cancer
pathway KEGG Thyroid cancer
disease MESH fallopian tube cancer
disease MESH myosarcoma
disease MESH hepatocellular carcinoma
pathway KEGG Hepatocellular carcinoma
disease MESH parathyroid cancer
disease MESH neuroendocrine carcinoma
disease MESH anal cancer
disease MESH yolk sac tumor
disease MESH sarcoma
disease MESH synovial sarcoma
drug DRUGBANK Methylergometrine
disease MESH coma
drug DRUGBANK L-Tyrosine
disease MESH lymphoma
drug DRUGBANK Sirolimus
disease VO population
disease IDO immunosuppression
disease MESH hematologic malignancy
drug DRUGBANK Imatinib
disease IDO cell
pathway REACTOME Reproduction
disease IDO infection prevalence
disease VO vaccine effectiveness
disease IDO infected population
disease IDO assay
disease VO organization
disease VO COVID-19 vaccine

Original Article

(Visited 1 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *